Qiong Deng, Shenzhen Pan, Fangzhou Du, Hongfei Sang, Zhixin Cai, Xiaoyu Xu, Qian Wei, Shuang Yu, Jingzhong Zhang, Chenglong Li
{"title":"血管生成素-1基因修饰的间充质干细胞条件培养基对糖尿病小鼠伤口愈合的影响。","authors":"Qiong Deng, Shenzhen Pan, Fangzhou Du, Hongfei Sang, Zhixin Cai, Xiaoyu Xu, Qian Wei, Shuang Yu, Jingzhong Zhang, Chenglong Li","doi":"10.3390/bioengineering11121244","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Mesenchymal stem cells (MSCs) have been introduced as a promising treatment for diabetic wounds. The effects of stem cell therapy are thought to be caused by bioactive molecules secreted by stem cells. Stem cell-based gene therapies can target bioactive molecules. Therefore, treatment using conditioned medium (CM) derived from genetically engineered stem cells has been proposed as an alternative option for diabetic ulcer care.</p><p><strong>Methods: </strong>MSCs derived from human umbilical cords were obtained and engineered to overexpress the angiogenin-1 gene (MSCs<sup>Ang1</sup>) through plasmid transfection. This study extracted conditioned medium from MSCs (MSC-CM) or MSCs<sup>Ang1</sup>(MSC<sup>Ang1</sup>-CM) for wound treatment applications. Via in vitro experiments, the proangiogenic effects of MSC<sup>Ang1</sup>-CM were assessed via the migration and tube formation of human umbilical vein endothelial cells (HUVECs). Furthermore, the efficacy of MSC<sup>Ang1</sup>-CM in promoting wound healing, re-epithelialization, hair follicle, and angiogenesis was evaluated via a diabetic mouse skin defect model.</p><p><strong>Results: </strong>In vitro assays demonstrated that MSC<sup>Ang1</sup>-CM significantly enhanced HUVECs' functions, including migration and tube formation. In vivo assays revealed that MSC<sup>Ang1</sup>-CM exhibited notable advancements in healing speed, re-epithelialization, hair follicle, and angiogenesis.</p><p><strong>Conclusion: </strong>These results indicate that MSC<sup>Ang1</sup>-CM can promote wound healing in diabetic mice and make the vascular structure in regenerated tissues more stable without inducing tissue fibrosis, providing a new therapeutic strategy for treating diabetic skin wounds. This provides a valuable theoretical basis for further research on regenerative medicine and cell therapy.</p>","PeriodicalId":8874,"journal":{"name":"Bioengineering","volume":"11 12","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673525/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Effect of Conditioned Medium from Angiopoietin-1 Gene-Modified Mesenchymal Stem Cells on Wound Healing in a Diabetic Mouse Model.\",\"authors\":\"Qiong Deng, Shenzhen Pan, Fangzhou Du, Hongfei Sang, Zhixin Cai, Xiaoyu Xu, Qian Wei, Shuang Yu, Jingzhong Zhang, Chenglong Li\",\"doi\":\"10.3390/bioengineering11121244\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Mesenchymal stem cells (MSCs) have been introduced as a promising treatment for diabetic wounds. The effects of stem cell therapy are thought to be caused by bioactive molecules secreted by stem cells. Stem cell-based gene therapies can target bioactive molecules. Therefore, treatment using conditioned medium (CM) derived from genetically engineered stem cells has been proposed as an alternative option for diabetic ulcer care.</p><p><strong>Methods: </strong>MSCs derived from human umbilical cords were obtained and engineered to overexpress the angiogenin-1 gene (MSCs<sup>Ang1</sup>) through plasmid transfection. This study extracted conditioned medium from MSCs (MSC-CM) or MSCs<sup>Ang1</sup>(MSC<sup>Ang1</sup>-CM) for wound treatment applications. Via in vitro experiments, the proangiogenic effects of MSC<sup>Ang1</sup>-CM were assessed via the migration and tube formation of human umbilical vein endothelial cells (HUVECs). Furthermore, the efficacy of MSC<sup>Ang1</sup>-CM in promoting wound healing, re-epithelialization, hair follicle, and angiogenesis was evaluated via a diabetic mouse skin defect model.</p><p><strong>Results: </strong>In vitro assays demonstrated that MSC<sup>Ang1</sup>-CM significantly enhanced HUVECs' functions, including migration and tube formation. In vivo assays revealed that MSC<sup>Ang1</sup>-CM exhibited notable advancements in healing speed, re-epithelialization, hair follicle, and angiogenesis.</p><p><strong>Conclusion: </strong>These results indicate that MSC<sup>Ang1</sup>-CM can promote wound healing in diabetic mice and make the vascular structure in regenerated tissues more stable without inducing tissue fibrosis, providing a new therapeutic strategy for treating diabetic skin wounds. This provides a valuable theoretical basis for further research on regenerative medicine and cell therapy.</p>\",\"PeriodicalId\":8874,\"journal\":{\"name\":\"Bioengineering\",\"volume\":\"11 12\",\"pages\":\"\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-12-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673525/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioengineering\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3390/bioengineering11121244\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/bioengineering11121244","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
The Effect of Conditioned Medium from Angiopoietin-1 Gene-Modified Mesenchymal Stem Cells on Wound Healing in a Diabetic Mouse Model.
Introduction: Mesenchymal stem cells (MSCs) have been introduced as a promising treatment for diabetic wounds. The effects of stem cell therapy are thought to be caused by bioactive molecules secreted by stem cells. Stem cell-based gene therapies can target bioactive molecules. Therefore, treatment using conditioned medium (CM) derived from genetically engineered stem cells has been proposed as an alternative option for diabetic ulcer care.
Methods: MSCs derived from human umbilical cords were obtained and engineered to overexpress the angiogenin-1 gene (MSCsAng1) through plasmid transfection. This study extracted conditioned medium from MSCs (MSC-CM) or MSCsAng1(MSCAng1-CM) for wound treatment applications. Via in vitro experiments, the proangiogenic effects of MSCAng1-CM were assessed via the migration and tube formation of human umbilical vein endothelial cells (HUVECs). Furthermore, the efficacy of MSCAng1-CM in promoting wound healing, re-epithelialization, hair follicle, and angiogenesis was evaluated via a diabetic mouse skin defect model.
Results: In vitro assays demonstrated that MSCAng1-CM significantly enhanced HUVECs' functions, including migration and tube formation. In vivo assays revealed that MSCAng1-CM exhibited notable advancements in healing speed, re-epithelialization, hair follicle, and angiogenesis.
Conclusion: These results indicate that MSCAng1-CM can promote wound healing in diabetic mice and make the vascular structure in regenerated tissues more stable without inducing tissue fibrosis, providing a new therapeutic strategy for treating diabetic skin wounds. This provides a valuable theoretical basis for further research on regenerative medicine and cell therapy.
期刊介绍：
Aims
Bioengineering (ISSN 2306-5354) provides an advanced forum for the science and technology of bioengineering. It publishes original research papers, comprehensive reviews, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. All aspects of bioengineering are welcomed from theoretical concepts to education and applications. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. There are, in addition, four key features of this Journal:
● We are introducing a new concept in scientific and technical publications “The Translational Case Report in Bioengineering”. It is a descriptive explanatory analysis of a transformative or translational event. Understanding that the goal of bioengineering scholarship is to advance towards a transformative or clinical solution to an identified transformative/clinical need, the translational case report is used to explore causation in order to find underlying principles that may guide other similar transformative/translational undertakings.
● Manuscripts regarding research proposals and research ideas will be particularly welcomed.
● Electronic files and software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.
● We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds.
Scope
● Bionics and biological cybernetics: implantology; bio–abio interfaces
● Bioelectronics: wearable electronics; implantable electronics; “more than Moore” electronics; bioelectronics devices
● Bioprocess and biosystems engineering and applications: bioprocess design; biocatalysis; bioseparation and bioreactors; bioinformatics; bioenergy; etc.
● Biomolecular, cellular and tissue engineering and applications: tissue engineering; chromosome engineering; embryo engineering; cellular, molecular and synthetic biology; metabolic engineering; bio-nanotechnology; micro/nano technologies; genetic engineering; transgenic technology
● Biomedical engineering and applications: biomechatronics; biomedical electronics; biomechanics; biomaterials; biomimetics; biomedical diagnostics; biomedical therapy; biomedical devices; sensors and circuits; biomedical imaging and medical information systems; implants and regenerative medicine; neurotechnology; clinical engineering; rehabilitation engineering
● Biochemical engineering and applications: metabolic pathway engineering; modeling and simulation
● Translational bioengineering
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
